Shenzhen Neptunus Interlong Bio-technique Company Limited (SEHK: 8329)
Health Care · Pharmaceuticals · HK
HK$0.11
+3.74% today · -29.7% 1Y
Shenzhen Neptunus Interlong Bio-technique Company Limited (SEHK: 8329) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $23.76M and employs 1,382 people.
Over the last twelve months the share price has lost 29.7%, trading between 0.09 and 0.18.
Tweenvest scores Shenzhen Neptunus Interlong Bio-technique Company Limited across four factors: quality 75/100, value 73/100, growth 0/100. Its strongest factor is quality.
8329 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $23.76M
- Revenue (TTM)
- $138.97M
- P/E
- —
- EPS
- -0.02
- Dividend yield
- —
- Beta (5Y)
- -0.13
- 52-week high
- HK$0.18
- 52-week low
- HK$0.09
- Avg volume (3M)
- —
- Shares outstanding
- 1.68B
- Employees
- 1,382
- Next earnings
- —
About Shenzhen Neptunus Interlong Bio-technique Company Limited
Based in Shenzhen, People's Republic of China, Shenzhen Neptunus Interlong Bio-technique Company Limited and its subsidiaries are primarily engaged in the research, development, production, and sale of pharmaceuticals. The company also handles the procurement, distribution, and marketing of medicines and health food items, while undertaking research and development in biological technology. Its manufacturing operations encompass herbal medicines, generic drugs, and medical devices. This entity operates as a subsidiary of Shenzhen Neptunus Bio-engineering Company Limited.
- ISIN
- CNE100000775
- Founded
- 2002
- Listed since
- Sep 12, 2005
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,251.05 | +0.33% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $270.67 | -0.87% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $152.72 | +1.37% |
| Roche Holding AGSWX: ROP | $368.80B | CHF370.70 | +0.08% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £122.08 | +0.81% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $27.93 | -0.14% |
Figures last refreshed Aug 18, 2026.